Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab combined with sintilimab for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2100051133Phase 2Not yet recruiting
- Sponsor
- Fifth Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fifth Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
nimotuzumabsintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100051133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051133.